SENSEX NIFTY

Sandoz

Jan 12, 2017 at 08:21 | Source: Moneycontrol.com
Bengaluru-based biopharmaceutical firm Biocon on Wednesday said US drug regulator has accepted its partners Mylans biologics license application (BLA) for the proposed biosimilar of breast cancer drug Trastuzumab through the 351(k) pathway.
Jan 09, 2017 at 14:06 | Source: Moneycontrol.com
Portuguese drug regulator Infarmed issued observations on January 3 after it detected non-conformities in good manufacturing practices related to the granulation and primary packaging of tablets in batches of drugs related to paracetamol and metformin supplied to Mylan, Bluepharma and Sandoz.
Feb 22, 2016 at 21:16 | Source: PTI
As many as 277,267 bottles of Candesartan Cilexetil tablets manufactured by Mylan Laboratories are being recalled by Sandoz Inc, for whom they were made, in an ongoing recall due to "failed impurities/degradation specifications; 9 month stability time point," the report said.
Nov 04, 2015 at 12:23 | Source: CNBC-TV18
Nexium (used to treat certain stomach and esophagus problem) & Pulmicort (used to prevent asthma attacks) supply may boost company's export formulation business during the quarter. Hence, export formulation business may grow around 35-40 percent year-on-year.
Oct 28, 2015 at 18:04 | Source: Reuters
The warning, issued to Novartis's generic drugs unit Sandoz on Oct. 22, came after FDA officials inspected its Turbhe and Kalwa sites in western India in August 2014.
Jul 30, 2015 at 13:10 | Source: Moneycontrol.com
Kotak has a buy rating on Cipla with a target price of Rs 730 per share. Expecting launch of other two strengths (USD 600 million) in days to follow , the brokerage says Cipla will receive mark-up and profit share.
Dec 23, 2014 at 20:21 | Source: PTI
The multi-layered deal involves UK-based GlaxoSmithKline (GSK) acquiring the Swiss major's vaccine business, while the latter would purchase GSK's cancer drugs portfolio.
Nov 07, 2014 at 10:04 | Source: Moneycontrol.com
Brokerages are worried about the stocks and stress that approval of Sun Pharma-Ranbaxy deal will be key driver. They feel that this negative surprise may benefit Dr Reddy's.
Nov 07, 2014 at 09:41 | Source: CNBC-TV18
Surajit Pal, pharma analyst, Prabhudas Lilladher, expects Teva, Mylan, Sandoz and Dr Reddys Laboratories to benefit from this loss.
Sep 01, 2014 at 11:38 | Source: CNBC-TV18
According to Surajit Pal, both Natco Pharma and Dr. Reddys share exclusivity and two-three more companies are also expected to join the same.
Messages on Sandoz »

axeumax009

New Member

17 Followers

Wockhardt  

and timelines show each company raising their prices by almost exactly the same amount within months of attending the meetings. wockhardt instituted price increases on its clobetasol product on the opening day of that meeting. then novartis s generic drug unit, sandoz ag, raised its own clobetasol prices about

3.55 PM Dec 16th 2016

manishshah3
73

New Member

7 Followers

Laurus Labs  

disclosure in this Draft Red Herring Prospectus in this context. .No Company Revenues (2015) (USD Bn) 1 Teva Pharmaceutical Industries 9.5 2 Sandoz 9.2 3 Mylan 8.17 4 Fresenius Kabi 5.9 5 Hospira (Now a part of Pfizer) 4.7 operators suvenlife ksk energy santha biotech medchal 6 Sun Pharmaceutical Industries

10.30 AM Dec 6th 2016

axeumax009

New Member

17 Followers

Wockhardt  

the global market for biosimilars is characterized by companies such as sandoz pharma, hospira, inc., actavis, , wockhardt ltd., biocon ltd. biosimilars for the pharmaceutical products such as insulin, human growth hormone, and blood products are considered as the high-interest market

12.47 PM Nov 4th 2016

dev78629

Silver Member

3 Followers

Novartis India  

again? In this light one interesting observation in the case of buyback of Clariant Chemicals (from the same stable of erstwhile Sandoz): the company bought back at 950 around one year back and the share is no where close to that price even after a year, infact it had gone to 585 levels since

2.14 PM Sep 16th 2016

moderate

Gold Member

44 Followers

Parabolic Drugs  

, Mexican and Chinese authorities and USFDA is in the pipeline. The company had signed long term contracts with Ranbaxy, Sun Pharma, Sandoz, Lupin, Midas (Germany), Pfizer (USA), Meiji(Japan), Summit Pharma (Japan), Alkem, Shinogi and Merck but due to deadlock situation in terms of funds availability

12.18 PM Sep 5th 2016

huensang

New Member

0 Follower

Biocon  

sandoz,celltrion & Samsung bioepis...

3.42 PM Aug 31st 2016

messenger17
91

Platinum Member

27 Followers

Novartis India  

Sandoz, the generic arm of Swiss drug maker Novartis, has decided to shut its facility for development of generic drugs in India Facility employed 157 people, who have been given notice till February

9.54 PM Jan 19th 2013

manishnb

Platinum Member

387 Followers

Aurobindo Pharm  

today one of our zydus r n d mr.S B Roy given speech regarding zydus cadila growth and he wil left company within 3 to 4 days but he admire growth of aurobindo, sun, teva, novartis, mylan and sandoz.

10.19 PM Dec 25th 2012

ash_chakra0
3

Platinum Member

72 Followers

Lupin  

, the company said. The oral contraceptive market in the US is valued at around $5 billion and growing at around 8-10 per cent annually and is dominated by few companies like Teva, Watson, Sandoz and Bayer. Shares of Lupin were trading at Rs 618.45 on the BSE in late afternoon trade, up 1.62 per cent from its

5.21 PM Dec 19th 2012

Web Messenger

Platinum Member

369226 Followers

Novartis India  

Source:Business Standard - Sandoz, the generic arm of Swiss drug maker Novartis, has decided to shut its facility for development of generic drugs in India. The facility, known as Sandoz Development Centre located near Mumbai, employed around 157 people, who have now been given notice till

2.42 PM Nov 30th 2012

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.